Literature DB >> 12848746

Is there a rationale for the continuous infusion of cefepime? A multidisciplinary approach.

E Bernard1, D Breilh, J-P Bru, D Chiche, I Dujardin, R Garraffo, F Goldstein, I Lavrard, G Potel.   

Abstract

This review is the fruit of multidisciplinary discussions concerning the continuous administration of beta-lactams, with a special focus on cefepime. Pooling of the analyses and viewpoints of all members of the group, based on a review of the literature on this subject, has made it possible to test the hypothesis concerning the applicability of this method of administering cefepime. Cefepime is a cephalosporin for injection which exhibits a broader spectrum of activity than that of older, third-generation cephalosporins for injection (cefotaxime, ceftriaxone, ceftazidime). The specific activity of cefepime is based on its more rapid penetration (probably due to its zwitterionic structure, this molecule being both positively and negatively charged) through the outer membrane of Gram-negative bacteria, its greater affinity for penicillin-binding proteins, its weak affinity for beta-lactamases, and its stability versus certain beta-lactamases, particularly derepressed cephalosporinases. The stability of cefepime in various solutions intended for parenteral administration has been studied, and the results obtained demonstrated the good compatibility of cefepime with these different solutions. These results thus permit the administration of cefepime in a continuous infusion over a 24-h period, using two consecutive syringes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848746     DOI: 10.1046/j.1469-0691.2003.00587.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  2 in total

1.  A novel extended-spectrum TEM-type beta-lactamase, TEM-138, from Salmonella enterica serovar Infantis.

Authors:  Chedly Chouchani; Renaud Berlemont; Afef Masmoudi; Moreno Galleni; Jean-Marie Frere; Omrane Belhadj; Kamel Ben-Mahrez
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Cefepime Dosing Requirements in Elderly Patients Attended in the Emergency Rooms.

Authors:  Jesus Ruiz-Ramos; Sergio Herrera-Mateo; Laia López-Vinardell; Ana Juanes-Borrego; Mireia Puig-Campmany; Maria Antonia Mangues-Bafalluy
Journal:  Dose Response       Date:  2022-02-25       Impact factor: 2.658

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.